Steinberg, Alexandra
CymaBay Therapeutics (United States) · Institutul Clinic Fundeni
2 papers on CoChatORCID 0009-0002-9548-509X
Most cited papers
- Verified
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology
Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors
Cited by 191
- Verified
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 127
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free